• P. N. Patsalos


Phenobarbital (Fig. 1) corresponds chemically to 5-ethyl-5-phenylbarbituric acid with an empirical formula of C12H12N2O3 and a molecular weight of 232.23.


Valproic Acid Plasma Clearance Tuberous Sclerosis Pharmacokinetic Interaction Seizure Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kelly WN, Richardson AP, Mason MF, Rector FC. Acetazolamide in phenobarbital intoxication. Arch Intern Med. 1966;117:64–9.CrossRefGoogle Scholar
  2. 2.
    Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing phenobarbitone levels in epileptic patients. Br J Clin Pharmacol. 1977;4:541–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Vakil SD, Critchley EMR, Cocks A, Hayward HW. The effect of clobazam on blood levels of phenobarbitone, phenytoin and carbamazepine (preliminary report). Royal Society of Medicine international congress and symposium series no. 43. London, 1981, p. 165–7.Google Scholar
  4. 4.
    Nanda RN, Johnson RH, Keogh HJ, Lambie DG, Melville ID. Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. J Neurol Neurosurg Psychiatry. 1977;40:538–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response ­relationships of eslicarbazepine acetate in adult patients with ­partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis. CNS Drugs. 2012;26:79–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Schmidt D. The effect of phenytoin and ethosuximide on primidone metabolism in patients with epilepsy. J Neurol. 1975;209:115–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW, Radwanski E, Mojavarian P, Lin CC, Nezamis J, Guillaume M, Affrime MB. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 1995;58:279–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol. 1991;31:171–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Eriksson AS, Hoppu K, Nergardh A, Boreu L. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia. 1996;37:769–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Perucca E, Baltes E, Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs). Epilepsia. 2000;41(Suppl):150.Google Scholar
  11. 11.
    Rambeck B. Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalized epileptic patients. Epilepsia. 1979;20:147–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, Moore A, Flesch G, Kramer L, D’Souza J. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–607.PubMedCrossRefGoogle Scholar
  13. 13.
    Lambie DG, Johnson RH. The effect of phenytoin on phenobarbitone and primidone metabolism. J Neurol Neurosurg Psychiatry. 1981;44:148–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia. 2011;52:405–9.PubMedGoogle Scholar
  15. 15.
    Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol. 2003;56:39–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Levy RH, Loiseau P, Guyot M, Blehaut H, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Summary of Product Characteristic, Sulthiame/Ospolot. 2009.Google Scholar
  19. 19.
    Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo ­controlled trials in outpatients with partial seizures. Epilepsia. 1995;36 (Suppl 3):158.Google Scholar
  20. 20.
    Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate–phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981;29:480–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia. 1986;27:115–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Spence SJ, Nakagawa J, Sankar R, Shields WD. Phenobarbital interferes with the efficacy of vigabatrin in treating infantile spasms in patients with tuberous sclerosis. Epilepsia. 2000;41 (Suppl 7):189.Google Scholar
  23. 23.
    Buchanan RA, Page JG, French JA, Leppik IE, Padgett CS. Zonisamide drug interactions. Epilepsia. 1997;38 (Suppl 8):107.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations